Lmcg Investments LLC Grows Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Lmcg Investments LLC raised its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 20.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 55,949 shares of the medical equipment provider’s stock after buying an additional 9,484 shares during the quarter. Lmcg Investments LLC’s holdings in Zimmer Biomet were worth $5,910,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in ZBH. Equity Investment Corp bought a new stake in Zimmer Biomet during the third quarter valued at approximately $70,104,000. Hotchkis & Wiley Capital Management LLC lifted its holdings in shares of Zimmer Biomet by 49.1% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after acquiring an additional 577,320 shares during the last quarter. Magnetar Financial LLC grew its position in Zimmer Biomet by 58.7% in the second quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider’s stock worth $142,203,000 after acquiring an additional 484,816 shares in the last quarter. Van ECK Associates Corp increased its stake in Zimmer Biomet by 12.4% in the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after acquiring an additional 411,163 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC purchased a new stake in Zimmer Biomet during the third quarter valued at about $41,588,000. 88.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Truist Financial increased their price target on shares of Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. Barclays decreased their target price on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research report on Thursday, December 12th. Raymond James cut their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Royal Bank of Canada increased their target price on Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Monday, November 4th. Finally, BTIG Research cut their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a report on Thursday, October 3rd. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $123.33.

Zimmer Biomet Trading Up 0.7 %

Zimmer Biomet stock opened at $109.65 on Tuesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The firm’s 50 day moving average price is $107.84 and its 200-day moving average price is $108.02. Zimmer Biomet Holdings, Inc. has a 1 year low of $100.67 and a 1 year high of $133.90. The stock has a market cap of $21.83 billion, a P/E ratio of 20.85, a PEG ratio of 1.88 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.65 EPS. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s payout ratio is 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.